XML 37 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 15: Subsequent Events

 

On October 5, 2022, the Delaware Court of Chancery held a hearing regarding a motion to require the AIM Board of Directors to accept the Jorgl Group’s director nominations and include the group’s nominees on a universal proxy card for the 2022 Annual Meeting of Stockholders. On October 28, 2022, the court denied Jorgl’s motion. The Jorgl Group announced on November 2, 2022, that it did not intend to appeal the decision.

 

On October 12, 2022, the Company announced that its Investigational New Drug (IND) application filed with the FDA was granted clearance to proceed and therefore the Company could initiate a Phase 2 study evaluating Ampligen as a therapeutic for patients with post-COVID conditions (“AMP-518”).

 

On November 1, 2022, AIM completed the sale of its facility at 783 Jersey Avenue, New Brunswick, N.J., for $3.7 million net of normal closing cost.

 

In November 2022, AIM received notice that the FDA had granted Orphan Drug Designation to Ampligen for the treatment of Ebola virus disease.